Lundbeck further strengthens pipeline by moving Lu AA34893 into clinical phase II

Bipolar disorder is a serious, life-long disorder, in which patients
suffer from episodes of depression (lows) alternated with episodes of
mania or hypomania (highs). This mood disorder usually starts early
in life and has a significant impact on the lives and relatives of
the patients.

The first patients in a 600-patient Phase II study have now been
enrolled. The study will investigate the effects of Lu AA34893 on the
depressive episodes in bipolar disorder and its potential to prevent
occurrence of mania.

Lu AA34893 was selected as a development candidate based on its
convincing effect in preclinical animal models suggesting a potential
to improve the treatment of mood disorder. The mechanism of action
for Lu AA34893 incorporates a number of monoaminergic systems and
includes allosteric effects. Thus, the compound has a potential
profile that is superior to other treatments currently used in
bipolar disorders."Lu AA34893 belongs to a new generation of psychotropics with a
strong potential to show long-term effective mood stabilisation and
thereby prevention of long-term disability in patients suffering from
bipolar disorder. This study marks the first entry into bipolar
disorder for Lundbeck and if successful, Lu AA34893 will provide a
completely new approach to treat the needs of patients with bipolar
disorder", said Senior Vice President Anders Gersel Pedersen, head of
Development at Lundbeck. "We are very pleased with the fact that
Lundbeck's development pipeline never has been as broad based as is
the case today."

About Lu AA34893
The in vitro pharmacological profile of the compound shows that the
compound combines potent effects on several serotonin receptors and
serotonin transporter proteins.

The content of this release have no influence on the Lundbeck Group's
financial result for 2007 being presented on 4 March 2008. On the
same occasion Lundbeck will present the expectations for the
financial result for 2008.


Lundbeck contacts


Investors:                    Media:

Jacob Tolstrup                Anders Schroll
Director, Corporate Reporting Head of Communication
+45 36 43 30 79               +45 36 43 20 81

Palle Holm Olesen
Head of Investor Relations
+45 36 43 24 26


                      ________________________

Stock Exchange Release No 324 - 18 February 2008

About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of drugs
for the treatment of psychiatric and neurological disorders. In 2006,
the company's revenue was DKK 9.2 billion (approximately EUR 1.2
billion or USD 1.6 billion). The number of employees is approximately
5,300 globally. For further information, please visit
www.lundbeck.com